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Available online 14 January 2016The KCL024 human embryonic stem cell line was derived from an embryo donated for research that carried an
autosomal dominant mutation in the NF1 gene encoding neuroﬁbromin (c.3739–3742 ΔTTTG). Mutations in
this gene have been linked to neuroﬁbromatosis type 1, juvenile myelomonocytic leukemia and Watson syn-
drome. The ICM was isolated using laser microsurgery and plated on γ-irradiated human foreskin ﬁbroblasts.
Both the derivation and cell line propagation were performed in an animal product-free environment. Pluripo-
tent state and differentiation potential were conﬁrmed by in vitro assays.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).InResource tableame of stem cell line KCL024
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Consenting process
Wedistribute Patient Information Sheet (PIS) and consent form to the
in vitro fertilization (IVF) patients if they opted to donate to research em-
bryos that were stored for 5 or 10 years. Theymail signed consent back to
us and that might be months after the PIS and consent were mailed to
them. If in the meantime new versions of PIS/consent are implemented,
we do not send these to the patients or ask them to re-sign; the whole
process is done with the version that was given them initially. The PIS/
consent documents (PGD-V.8) were created on Jul. 01, 2010. HFEA
Code of Practice that was in effect at the time of document creation: Edi-
tion 8 — R.2 (http://www.hfea.gov.uk/2999.html). The donor couple
signed the consent on Oct. 28, 2010. HFEA Code of Practice that was in ef-
fect at the time of donor signature: Edition 8— R.2. HFEA Code of Practice
Edition 8— R.2 was in effect 07 Apr. 2010–Apr. 06, 2011.
Embryo culture and micromanipulation
Embryo culture and laser-assisted dissection of inner cell mass
(ICM) were carried out as previously described in details (Ilic et al.,
2012; Stephenson et al., 2012). The cellular area containing the ICM
was then washed and transferred to plates containing mitotically
inactivated human neonatal foreskin ﬁbroblasts (HFF).
Cell culture
ICMplated onmitotically inactivatedHFFwere cultured as described
(Ilic et al., 2012; Stephenson et al., 2012). TE cells were removed me-
chanically from outgrowth (Ilic et al., 2007; Ilic et al., 2010). hESC colo-
nies were expanded and cryopreserved at the third passage.
Viability test
Straws with the earliest frozen passage (p.2–3) are thawed and new
colonies are counted three days later. These colonies are then expandedt4, Nanog, TRA-1-60, TRA-1-81) and alkaline phosphatase (AP) activity assay. Scale bar,
Fig. 3. Differentiation of three germ layers in vitro is conﬁrmed by detection of markers: smooth muscle actin (ACTA2, red) for mesoderm, β-III tubulin (TUBB3, red) for ectoderm andα-
fetoprotein (AFP, red) for endoderm. Nuclei are visualized with Hoechst 33342 (blue). Scale bar, 100 μm.
245H. Hewitson et al. / Stem Cell Research 16 (2016) 243–245up to passage 8, atwhich point cells were part frozen and part subjected
to standard battery of tests (pluripotency markers, in vitro and in vivo
differentiation capability, genetics, sterility, mycoplasma).
Pluripotency markers
Pluripotencywas assessed using two different techniques: enzymat-
ic activity assay [alkaline phosphatase (AP) assay] and immunostaining
as described (Ilic et al., 2012; Stephenson et al., 2012).
Differentiation
Spontaneous differentiation into three germ layers was assessed
in vitro as described (Ilic et al., 2012; Stephenson et al., 2012; Petrova
et al., 2014).
HLA typing
HLA-A, -B and -DRB1 typing was performed with a PCR sequence-
speciﬁc oligonucleotide probe (SSOP; Luminex, Austin, TX, USA) hybrid-
ization protocol at the certiﬁed Clinical Transplantation Laboratory,
Guy's and St. Thomas' NHS Foundation Trust and Serco Plc. (GSTS) Pa-
thology (Guy's Hospital, London, UK) as described (Jacquet et al., 2013).
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